Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp has secured a key European patent for its innovative thiol compounds, enhancing its global intellectual property portfolio. The patent supports the company’s lead compound, TTI-0102, which aims to combat oxidative stress, a factor in chronic diseases like mitochondrial disorders and diabetes.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.